-
Start Preamble
Start Printed Page 2907
Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 21, 2006, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:
Drug Schedule Tetrahydrocannabinols (7370) I Dihydromorphine (9145) I Dihydrocodeine (9120) II Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II Sufentanil (9740) II Fentanyl (9801) II Remifentanil (9739) II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than March 26, 2007.
Start SignatureDated: January 16, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-850 Filed 1-22-07; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 01/23/2007
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- E7-850
- Pages:
- 2907-2907 (1 pages)
- PDF File:
- e7-850.pdf